MLYS net incomeQ3 2026-$57.33M
MLYS net income was -$57.33M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$36.93M a year earlier. For the full fiscal 2025 it was -$154.65M, compared with -$177.81M in fiscal 2024.
Mineralys Therapeutics Inc. (MLYS) financials
For the twelve months ended Sep 30, 2026, Mineralys Therapeutics Inc. reported -$369.97M of net income.
- Net income, TTM
- -$369.97M
- Cash
- $101.27M
- Total debt
- $100.0K
- Market cap
- $1.36B
FY2022FY2025
FY2023FY2025
MLYS revenue and earnings growth
MLYS EPSQ3 2026-$0.64
MLYS diluted EPS was -$0.64 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.52 a year earlier. For the full fiscal 2025 it was -$2.29, compared with -$3.66 in fiscal 2024.
MLYS free cash flowQ4 2025-$37.90M
MLYS free cash flow was -$37.90M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$66.84M a year earlier. For the full fiscal 2025 it was -$142.43M, compared with -$166.41M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Research and development | $132.01M | $168.58M | $70.36M | $26.25M |
| Selling, general and admin | $38.59M | $23.82M | $14.30M | $5.23M |
| Operating income | -$170.60M | -$192.40M | -$84.66M | -$31.48M |
| Income tax | $0 | - | - | - |
| Net income | -$154.65M | -$177.81M | -$71.90M | -$29.80M |
| EPS, basic | -$2.29 | -$3.66 | -$1.99 | -$5.77 |
| EPS, diluted | -$2.29 | -$3.66 | -$1.99 | -$5.77 |
| Diluted shares | 67.7M | 48.5M | 36.2M | 5.2M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $172.92M | $114.09M | $49.30M | $87.70M |
| Current assets | $661.39M | $205.35M | $249.10M | $112.81M |
| Total assets | $661.81M | $205.90M | $251.64M | $114.44M |
| Current liabilities | $15.11M | $14.65M | $10.48M | $8.07M |
| Total liabilities | $15.11M | - | - | - |
| Shareholders' equity | $646.69M | $191.26M | $241.15M | -$52.27M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$142.42M | -$166.31M | -$81.17M | -$29.22M |
| Capital expenditures | $15.0K | $96.0K | $0 | - |
| Free cash flow | -$142.43M | -$166.41M | -$81.17M | - |
| Investing cash flow | -$389.75M | $114.96M | -$160.47M | -$21.76M |
| Financing cash flow | $591.00M | $116.14M | $203.25M | $128.02M |
| Stock-based compensation | $19.32M | $11.34M | $5.06M | $455.0K |
| Depreciation and amortization | $59.0K | $43.0K | $0 | - |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $22.67M | $221.38M | $24.36M | $24.40M | $31.45M | $38.28M | $37.88M | $44.57M | $53.98M | $39.27M | $30.75M | $23.68M |
| Selling, general and admin | $37.42M | $24.66M | $20.98M | $13.88M | $9.68M | $8.47M | $6.57M | $7.20M | $6.12M | $5.89M | $4.61M | $4.03M |
| Operating income | -$60.09M | -$246.04M | -$45.34M | -$38.28M | -$41.13M | -$46.75M | -$44.45M | -$51.77M | -$60.11M | -$45.17M | -$35.36M | -$27.71M |
| Interest expense | $3.19M | - | - | - | $0 | - | - | - | - | - | - | - |
| Income tax | - | - | - | $0 | - | - | - | - | - | - | - | - |
| Net income | -$57.33M | -$241.07M | -$39.34M | -$32.23M | -$36.93M | -$43.27M | -$42.21M | -$48.95M | -$56.34M | -$41.01M | -$31.51M | -$24.39M |
| EPS, basic | -$0.64 | -$2.85 | -$0.47 | - | -$0.52 | -$0.66 | -$0.79 | -$1.00 | -$1.13 | -$0.83 | -$0.70 | - |
| EPS, diluted | -$0.64 | -$2.85 | -$0.47 | - | -$0.52 | -$0.66 | -$0.79 | -$1.00 | -$1.13 | -$0.83 | -$0.70 | - |
| Diluted shares | 89.0M | 84.7M | 82.8M | - | 70.6M | 65.5M | 53.2M | - | 49.8M | 49.4M | 44.9M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $101.27M | $138.27M | $112.78M | $172.92M | $217.60M | $101.79M | $165.01M | $114.09M | $97.27M | $67.86M | $90.42M | $49.30M |
| Current assets | $627.99M | $665.80M | $652.47M | $661.39M | $599.80M | $335.27M | $354.51M | $205.35M | $267.73M | $318.00M | $346.82M | $249.10M |
| Total assets | $630.12M | $667.85M | $652.86M | $661.81M | $599.95M | $335.72M | $354.94M | $205.90M | $268.25M | $318.49M | $347.25M | $251.64M |
| Current liabilities | $53.08M | $19.32M | $14.72M | $15.11M | $23.52M | $22.17M | $13.39M | $14.65M | $31.32M | $28.40M | $19.20M | $10.48M |
| Total debt | $100.0K | $100.0K | - | - | - | - | - | - | - | - | - | - |
| Total liabilities | $126.35M | $116.94M | - | $15.11M | - | - | - | - | - | - | - | - |
| Shareholders' equity | $503.77M | $550.92M | $638.14M | $646.69M | $576.43M | $313.55M | $341.56M | $191.26M | $236.93M | $290.10M | $328.05M | $241.15M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.10M | -$32.56M | -$39.47M | -$37.89M | -$28.87M | -$30.17M | -$45.49M | -$66.84M | -$50.19M | -$30.15M | -$19.14M | -$28.98M |
| Capital expenditures | - | - | - | $15.0K | $0 | $0 | $0 | $0 | $37.0K | $0 | $59.0K | $0 |
| Free cash flow | - | - | - | -$37.90M | -$28.87M | -$30.17M | -$45.49M | -$66.84M | -$50.22M | -$30.15M | -$19.20M | -$28.98M |
| Investing cash flow | $4.70M | -$185.22M | -$44.94M | -$103.49M | -$150.51M | -$42.88M | -$92.88M | $83.57M | $79.61M | $7.74M | -$55.95M | -$8.09M |
| Financing cash flow | $1.40M | $243.26M | $24.27M | $96.70M | $295.19M | $9.83M | $189.28M | $90.0K | -$1.0K | -$152.0K | $116.20M | $74.0K |
| Stock-based compensation | $7.88M | $7.36M | $6.55M | $5.29M | $5.84M | $4.55M | $3.65M | $3.13M | $3.14M | $2.87M | $2.19M | $1.46M |
| Depreciation and amortization | $6.0K | $5.0K | $6.0K | $13.0K | $15.0K | $16.0K | $15.0K | $15.0K | $11.0K | $9.0K | $8.0K | $0 |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 11.83 | 34.46 | 44.33 | 43.76 | 25.50 | 15.12 | 26.48 | 14.02 | 8.55 | 11.20 | 18.06 | 23.76 |
| Debt to equity | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - |
Source: XBRL data Mineralys Therapeutics Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
MLYS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MLYS | - | - | -$369.97M | - | $1.36B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
MLYS FAQ
4 questionsIs MLYS profitable?
No. Mineralys Therapeutics Inc. reported a net loss of $369.97M for the twelve months ended Sep 30, 2026.How much cash and debt does MLYS have?
Mineralys Therapeutics Inc. reported $101.27M in cash and cash equivalents and $100.0K of debt on its most recent balance sheet in SEC filings.When did MLYS last report financial results?
The latest statements here come from Mineralys Therapeutics Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.Where does this MLYS financial data come from?
Quantisnow builds these statements from the structured XBRL data Mineralys Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.